日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Circulating tumor DNA in neoadjuvant endocrine therapy for early breast cancer

循环肿瘤DNA在早期乳腺癌新辅助内分泌治疗中的应用

Grinshpun, A; Dustin, D; Cai, M; Hughes, M; DiLullo, M; Moore, M; Yardley, D; Mayer, I A; Symmans, W F; Mayer, E L; Winer, E P; Lin, N U; Tolaney, S M; Metzger, O; Jeselsohn, R

Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer.

定量 HER2 组织和血浆分析可预测曲妥珠单抗 deruxtecan 对乳腺癌的活性。

Tarantino Paolo, Kim Se-Eun, Hughes Melissa E, Kusmick Ross J, Smith Kalie, Brasó-Maristany Fara, Nyein Chan Nay Nwe, Paré Brunet Laia, Alder Laura, Garcia-Cortes Diana, Gomez Tejeda Zanudo Jorge, Pereslete Alyssa M, Noteware Laura, Moore Heather, Van Swearingen Amanda E D, Li Tianyu, Gupta Hersh, D'Amico Olivia, Martini Alba, Morganti Stefania, Spindel Jennifer, Cook Charmaine, McLaughlin Christine, Dvir Kathrin, Garrido-Castro Ana C, Sammons Sarah, Files Janet, Sendrick Kerry, Buck Simone, Dillon Deborah, Jeselsohn Rinath, Li Yvonne Y, Cherniack Andrew D, LoRusso Patricia, Lustberg Maryam, Vega-León Rosario, Pardo Francisco, Davis Justin, Mueller Claudius, Corgiat Brian, Curigliano Giuseppe, Anders Carey K, Petricoin Emanuel F, Rimm David L, Prat Aleix, Tayob Nabihah, Lin Nancy U, Tolaney Sara M

Androgen receptor expression and immune characteristics of HER2-low metastatic triple-negative breast cancer

HER2低表达转移性三阴性乳腺癌的雄激素受体表达和免疫特征

Tarantino, Paolo; Cha, Jaeyoon; Binboga Kurt, Busem; Chu, Xiangying; Jovanović, Bojana; Zhou, Andrew; Hughes, Melissa; Russo, Douglas; DiLullo, Molly; Wrabel, Eileen; Jeselsohn, Rinath; Lin, Nancy U; Carter, Jamie; Chen, Yisang Serenity; Li, Tianyu; Tayob, Nabihah; Mittendorf, Elizabeth A; Schnitt, Stuart J; Goel, Shom; Tolaney, Sara M

The CHI3L1-neutrophil axis drives immune suppression and breast cancer metastatic dissemination.

CHI3L1-中性粒细胞轴驱动免疫抑制和乳腺癌转移扩散。

Taifour Tarek, Massé Adéline, Gu Yu, Sanguin-Gendreau Virginie, Zuo Dongmei, Xiao Bin, Solymoss Emilie, Shen Yunyun, Proud Hailey, Attalla Sherif Samer, Papavasiliou Vasilios, Lin Nancy U, Hughes Melissa E, Smith Kalie, Lee Chun Geun, Kamle Suchitra, Ursini-Siegel Josie, Elias Jack A, Siegel Peter M, Jeselsohn Rinath, Muller William J

Tamoxifen induces PI3K activation in uterine cancer.

他莫昔芬可诱导子宫癌细胞中PI3K活化。

Kübler Kirsten, Nardone Agostina, Anand Shankara, Gurevich Daniel, Gao Jianjiong, Droog Marjolein, Hermida-Prado Francisco, Akhshi Tara, Feiglin Ariel, Feit Avery S, Cohen Feit Gabriella, Dackus Gwen, Pun Matthew, Kuang Yanan, Cha Justin, Miller Mendy, Gregoricchio Sebastian, Lanfermeijer Mirthe, Cornelissen Sten, Gibson William J, Paweletz Cloud P, Van Allen Eliezer M, van Leeuwen Flora E, Nederlof Petra M, Nguyen Quang-Dé, Mourits Marian J E, Radovich Milan, Leshchiner Ignaty, Stewart Chip, Matulonis Ursula A, Zwart Wilbert, Maruvka Yosef E, Getz Gad, Jeselsohn Rinath

Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS)

纳武利尤单抗联合低剂量伊匹木单抗治疗高突变 HER2 阴性转移性乳腺癌:一项 II 期试验 (NIMBUS)

Barroso-Sousa, Romualdo; Zanudo, Jorge Gomez Tejeda; Li, Tianyu; Reddy, Sangeetha M; Emens, Leisha A; Kuntz, Thomas M; Silva, Carolina Alves Costa; AlDubayan, Saud H; Chu, Hoyin; Overmoyer, Beth; Lange, Paulina; DiLullo, Molly K; Montesion, Meagan; Kasparian, Julie; Hughes, Melissa E; Attaya, Victoria; Basta, Ameer; Lin, Nancy U; Tayob, Nabihah; Jeselsohn, Rinath; Mittendorf, Elizabeth A; Tolaney, Sara M

Combined inhibition of KAT6A/B and Menin reverses estrogen receptor-driven gene expression programs in breast cancer

联合抑制KAT6A/B和Menin可逆转乳腺癌中雌激素受体驱动的基因表达程序

Sarah Naomi Olsen,Bryn Anderson,Charlie Hatton,Zhengtao Chu,Christopher Simpkins,Yanhe Wen,Wallace Bourgeois,Elena L Haarer,Myles Brown,Rinath Jeselsohn,Alana L Welm,Eneda Toska,Scott A Armstrong

A Phase II Study of Abemaciclib for Patients with Retinoblastoma-Positive, Metastatic Triple-Negative Breast Cancer

一项针对视网膜母细胞瘤阳性、转移性三阴性乳腺癌患者的阿贝西利II期研究

Goel, Shom; Jovanović, Bojana; Chu, Xiangying; Hughes, Melissa; Erick, Timothy K; Russo, Douglas; DiLullo, Molly; Wrabel, Eileen; Jeselsohn, Rinath; Lin, Nancy U; Tayob, Nabihah; Mittendorf, Elizabeth; Schnitt, Stuart; Tolaney, Sara M

Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2

对 HER2 阴性乳腺癌的分子特征分析揭示了一个独特的患者亚群,该亚群具有 17q12 缺失和 ERBB2 杂合性缺失。

Qiu, X; Tarantino, P; Li, R; Grinshpun, A; Gupta, H; Hughes, M E; Kirkner, G; Scholl, L; Johnson, B E; Meyerson, M; Cherniack, A D; Jiang, Y; Zhou, N; Lin, N U; Long, H W; Tolaney, S M; Jeselsohn, R

Response to letter re: Molecular characterization of HER2 negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2

回复关于“HER2阴性乳腺癌的分子特征分析揭示了一个具有17q12缺失和ERBB2杂合性缺失的独特患者亚组”的来信

Qiu, X; Tarantino, P; Tolaney, S; Jeselsohn, R